Adar Poonawalla, CEO, Serum Institute of India. file photo
Foreign Minister S Jaishankar: Serum Institute of India has tied up with AstraZeneca for the Oxford University vaccine. This vaccine is being produced in India under the name of Covishield.
New Delhi. Serum Institute of India CEO Adar Poonawalla on Friday thanked the US government and the Indian foreign minister. In fact, the US government has lifted restrictions on the coronavirus vaccine AstraZeneca, Novavax and Sanofi. Poonawalla tweeted that this decision of the US government will help in increasing the supply of raw materials globally and for India. This will also increase the production capacity of the vaccine and strengthen the fight against the epidemic.
In response to Poonawalla’s tweet, External Affairs Minister S. Jaishankar said that India’s diplomacy is to make the supply of corona vaccine safe. Let us tell you that on Thursday, the US administration disclosed its plan to share the vaccine with the global community. Also removed the Defense Production Act priority rating on AstraZeneca, Novavax and Sanofi vaccines. With this decision of the US administration, companies will now be able to decide to whom they have to sell the vaccine.
The White House said in its statement, “Vaccine manufacturers can continue to manufacture all three vaccines, according to this rule, US-based manufacturers will now be able to decide for themselves which vaccine orders to fulfill first and which later.” “
Serum Institute of India has tied up with AstraZeneca for the Oxford University vaccine. This vaccine is being produced in India under the name of Covishield. The company had trialed the vaccine in India and Kovashield was also supplied to the World Health Organization’s vaccine alliance Covox Organization. Serum Institute has also tied up with the Novavax company, whose vaccine will be known as Kovavax. Earlier, Adar Poonawalla raised the issue of restrictions imposed by the US on the supply of vaccine raw materials. In February, the US imposed restrictions on the supply of raw materials and said in defense of its decision that first it has to ensure the availability of the vaccine to the American people.